NCT07255157

Brief Summary

The aim is to determine whether whether Tph could support non-infectious complications through providing help to pathological B-cells.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
15mo left

Started Jul 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress16%
Jul 2026Jan 2028

First Submitted

Initial submission to the registry

November 19, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

November 28, 2025

Completed
7 months until next milestone

Study Start

First participant enrolled

July 9, 2026

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2028

Last Updated

August 5, 2026

Status Verified

August 1, 2026

Enrollment Period

1.5 years

First QC Date

November 19, 2025

Last Update Submit

August 3, 2026

Conditions

Keywords

common variable immunodeficiencyperipheral helper T cellsB cells

Outcome Measures

Primary Outcomes (1)

  • Ability of Tph to promote differentiation and antibody production by memory B cells (B-T co-culture)

    At baseline (Day 0)

Study Arms (2)

Common variable immunodeficiency

EXPERIMENTAL
Other: blood sample

Controls

ACTIVE COMPARATOR

Healthy controls

Other: blood sample

Interventions

48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation

Common variable immunodeficiencyControls

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female;
  • Age ≥ 18 years;
  • Being affiliated to health insurance;
  • Willing to participate and to sign informed consent.

You may not qualify if:

  • Patients on corticosteroids and/or immunosuppressants;
  • Patients with a primary immunodeficiency genetically characterized, such as Bruton disease our HyperIgM syndrome;
  • Patients with an active chronic infection;
  • Pregnant or breastfeeding women;
  • Persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Bordeaux - service de médecine interne

Pessac, France

RECRUITING

MeSH Terms

Conditions

Common Variable Immunodeficiency

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Immunologic Deficiency SyndromesImmune System Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Jean-François VIALLARD, Prof

    University Hospital, Bordeaux

    PRINCIPAL INVESTIGATOR
  • Jonathan VISENTIN, Prof

    University Hospital, Bordeaux

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 19, 2025

First Posted

November 28, 2025

Study Start

July 9, 2026

Primary Completion (Estimated)

January 1, 2028

Study Completion (Estimated)

January 1, 2028

Last Updated

August 5, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations